Stock Analiz

Arcadia Biosciences, Inc. RKDA

Oil & Gas Production · IPO 2015 · data as of November 13, 2026

$0.22Market cap $1M
Open the interactive analysis →

Arcadia Biosciences, Inc. (RKDA) is a energy company listed in the US with a market value of about $1M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$10M, a net margin of -202.1%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -10% a year, a 5-year average ROIC of -51%.

About Arcadia Biosciences

Arcadia Biosciences is listed in the US and classified in oil & gas production, IPO year 2015. Revenue went from $7M in 2014 to $5M in 2025, a decline of about 3.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 128% over three years (dilution for shareholders). It spends 0% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health4/5
Shareholder returns1/5

Checks passed

  • Profit margin improving
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.3
P/B0.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-358.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-3.7%
Revenue growth (5 yrs, per year)-9.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-185.0%
ROIC (5-yr avg.)-51.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$5M$5M$5M$4M$7M$7M$8M$1M$1M$4M$3M
Net income-$10M-$2M-$7M-$14M-$15M-$15M-$5M-$29M-$13M-$16M-$20M
Free cash flow—-$5M-$10M-$15M-$14M-$27M-$33M-$19M-$14M-$14M-$17M
EPS (diluted)$-4.89$-1.71$-5.17$-11.29$-25.65$-27.56$-0.47$-4.53$-3.58$-7.28$-8.85
Net margin-202.1%-48.1%-139.5%-313.9%-207.3%-216.2%-57.9%-2464.1%-920.8%-390.1%-615.6%
ROIC—-47.7%-45.2%-34.8%-48.0%-81.6%-33.8%-154.0%-104.0%-141.2%-31.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Arcadia Biosciences pay a dividend?

Not currently.

Is Arcadia Biosciences a good stock to buy?

We do not give buy or sell advice. Arcadia Biosciences scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.